Atherosclerosis (Basics) — Pathophysiology, Risk Modification, Diagnostics • thevitatrack.com
1 Pathophysiology (sequence and biology) ▾
  • Endothelial dysfunction: shear stress, hypertension, hyperglycemia, and tobacco toxins impair nitric oxide signaling and barrier integrity.
  • Subendothelial LDL retention: ApoB-containing particles infiltrate and bind intimal proteoglycans; susceptibility increases with small dense LDL and elevated non-HDL-C.
  • Oxidative modification & innate immunity: oxidized LDL triggers macrophage recruitment, foam-cell formation, and cytokine release.
  • Plaque progression: necrotic core, neovascularization, fibrous cap remodeling; thin-cap fibroatheroma prone to rupture → thrombosis.
  • Clinical expression: CAD, cerebrovascular disease, and PAD via flow limitation and/or plaque rupture with thrombosis.
2 Risk stratification, lipid targets, adjunctive goals ▾

Risk tiers (conceptual)

  • Very high risk: ASCVD or equivalents (e.g., prior MI, stroke/TIA, symptomatic PAD), diabetes with target-organ damage, or markedly elevated LDL-C.
  • High risk: multiple risk factors (age, hypertension, smoking, CKD, strong family history) or high coronary calcium.
  • Intermediate/primary prevention: elevated calculated 10-yr risk without established ASCVD.

Targets (typical frameworks)

  • LDL-C: stepwise reduction with threshold-based intensification; non-HDL-C as secondary target when triglycerides are elevated.
  • Blood pressure: individualized control to reduce shear stress and cerebrovascular/coronary events.
  • Glycemia: A1C targets individualized; insulin resistance contributes to atherogenesis.
  • Weight/waist, smoking status, physical activity: direct impact on lipid phenotype and endothelial biology.
3 Diagnostics & imaging ▾
  • Lipids: fasting or non-fasting lipid panel (LDL-C, HDL-C, TG, non-HDL-C); ApoB and Lp(a) in selected contexts (familial risk, premature ASCVD).
  • Coronary artery calcium (CAC): refines risk in borderline cases; higher CAC indicates higher event rates.
  • Functional testing: stress ECG, stress echo, or nuclear perfusion for symptomatic patients or ambiguity.
  • CT coronary angiography: plaque characterization; useful in selected diagnostic scenarios.
  • Vascular beds: carotid duplex (stenosis), ABI for PAD (with toe-brachial index when calcified vessels).
4 Therapeutics: lipid lowering & risk modification ▾

Lipids (evidence-based)

  • Statins: first-line LDL-C lowering; robust outcome reduction across risk categories.
  • Ezetimibe: adjunct or alternative for further LDL-C reduction.
  • PCSK9 inhibitors: potent LDL-C lowering for very high risk or familial hypercholesterolemia.
  • Hypertriglyceridemia: address secondary causes; consider prescription omega-3s or fibrates when severe (pancreatitis risk mitigation).

Global risk control

  • Antiplatelet therapy: secondary prevention per indication; avoid routine primary prevention without clear net benefit.
  • Blood pressure control: reduce afterload and vascular injury dynamics; home BP logs improve titration.
  • Glycemic management: individualized A1C with attention to hypoglycemia and renal status.
  • Tobacco cessation, weight optimization, activity prescription: foundational for endothelial recovery.
5 Nutrition & activity prescriptions ▾

Dietary pattern

  • Mediterranean-style: vegetables, legumes, whole grains, nuts/seeds, olive oil; fish ≥2×/week.
  • Reduce industrial trans fats; moderate saturated fat; prioritize unsaturated fats.
  • Soluble fiber (oats, barley, pulses) for LDL-C reduction; sodium moderation supports BP control.

Activity

  • Regular aerobic volume (e.g., brisk walking), plus resistance and balance work as appropriate.
  • Progressive, individualized dosing with attention to orthopedic and cardiopulmonary status.
6 Monitoring & follow-up ▾
  • Lipids: recheck 6–12 weeks post-initiation/intensification, then 3–12 months per stability and risk.
  • BP/A1C/weight/waist: track per comorbid status and therapeutic changes.
  • Adherence & tolerance: review muscle symptoms, interactions, and lifestyle adherence; adjust therapy accordingly.
7 Red-flag presentations (urgent evaluation) ▾
  • Acute chest pain/pressure (especially with radiation, dyspnea, diaphoresis, or nausea).
  • Focal neurologic deficit (sudden weakness, facial droop, speech/vision change).
  • Acute limb ischemia signs (pain, pallor, pulselessness, paresthesia, paralysis, poikilothermia).
  • Syncope with exertion or palpitations/new arrhythmia symptoms.
  • Rest pain or non-healing ulcers in peripheral artery disease.
  • Severe shortness of breath at rest or new orthopnea.
Emergency: When in doubt, call emergency services immediately.
8 Practical checklist (clinic workflow) ▾

Baseline

  • Lipids: LDL-C, HDL-C, TG, non-HDL-C; consider ApoB, Lp(a).
  • BP, A1C (or fasting glucose), CMP (liver/renal), TSH if indicated.
  • ASCVD risk estimate; CAC for risk refinement if borderline.

Initiate/adjust

  • Start/intensify statin per risk; add ezetimibe or PCSK9i if needed.
  • Antiplatelet for secondary prevention; avoid routine primary prevention.
  • Lifestyle Rx: diet pattern, activity minutes/week, tobacco plan.

Follow-up

  • Recheck lipids 6–12 weeks; document % LDL-C change and absolute level.
  • Assess symptoms/side effects; review adherence and interactions.
  • Adjust targets with age, comorbidity, and tolerance.
9 FAQs ▾

Is atherosclerosis reversible?

Plaque stabilization and partial regression are possible with intensive LDL-C lowering and risk-factor control. Preventing progression and rupture is the core aim.

Do I need fasting labs?

Non-fasting panels are often acceptable; fasting may be preferred when triglycerides are high or for baseline comparability. Follow lab instructions.

What if I can’t tolerate a statin?

Options include dose/agent change, alternate-day dosing, ezetimibe, or PCSK9 inhibitors. Discuss risks/benefits and monitoring with your clinician.

10 Related guides on thevitatrack.com ▾

⬆️ Back to top

Educational content only. Not a substitute for professional medical advice. Always follow your clinician’s instructions.